UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of ~~report~~Report (Date of earliest event reported): ~~November~~March 36, ~~2025~~2026

Solid Biosciences Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-38360

90-0943402

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

500 Rutherford Avenue, Third Floor

Charlestown, Massachusetts 02129

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (617) 337-4680

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Trading Symbol~~TradingSymbol		Name of each exchange on which registered
Common Stock $0.001 par value per share		SLDB		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 21.~~02.~~01 ~~Results~~Entry ofinto ~~Operations~~a ~~and~~Material ~~Financial~~Definitive ~~Condition~~Agreement.

OnSecurities ~~November 3,~~Purchase ~~2025,~~Agreement Solid Biosciences Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

~~The~~On ~~information~~March 6, ~~provided~~2026, ~~under~~Solid ~~Item~~Biosciences 2Inc.02, ofa ~~this~~Delaware ~~Current~~corporation ~~Report~~(the on“Company”), ~~Form~~entered ~~8-K~~into a securities purchase agreement (~~including~~the ~~Exhibit~~“Securities ~~99.1~~Purchase Agreement”) ~~shall~~with ~~not~~certain beinstitutional ~~deemed~~accredited investors (the “~~filed~~Investors”), ~~for~~pursuant ~~purposes~~to ofwhich ~~Section 18~~the ofCompany agreed to issue and sell to the ~~Securities~~Investors ~~Exchange~~in ~~Act~~a private placement an aggregate of ~~1934~~14,973,257 asshares ~~amended~~of (the ~~“Exchange~~Company’s ~~Act”)~~common stock, orpar ~~otherwise~~value ~~subject~~$0.001 toper share (the ~~liabilities~~“Shares”), at a price of ~~that~~$5.61 ~~section~~per share, ~~nor~~and, ~~shall~~to itinvestors bewho ~~deemed~~so ~~incorporated~~choose byin ~~reference~~lieu inof ~~any~~Shares, ~~filing~~pre-funded ~~under~~warrants ~~the~~to ~~Securities~~purchase ~~Act~~27,807,482 shares of ~~1933,~~the asCompany’s ~~amended~~common stock (the “~~Securities~~Pre-Funded ~~Act~~Warrants”), orat ~~the~~a ~~Exchange~~price ~~Act,~~of ~~except~~$5.609 asper ~~expressly~~Pre-Funded ~~set~~Warrant ~~forth~~(the by“Private ~~specific reference in such a filing~~Placement”).

~~Item~~The 7Private Placement is expected to close on or about March 9, 2026, subject to the satisfaction of certain customary closing conditions.01 The Company expects to receive aggregate gross proceeds from the Private Placement of approximately $240.0 million, ~~Regulation~~before FDdeducting ~~Disclosure~~placement agent fees and offering expenses, and aggregate net proceeds from the Private Placement of approximately $226.8 million, after deducting placement agent fees.

OnLeerink ~~November 3,~~Partners ~~2025,~~LLC ~~the~~and ~~Company~~Citigroup ~~announced~~Global ~~positive~~Markets ~~new~~Inc. ~~interim~~acted ~~data~~as ~~from~~joint ~~its~~lead ~~Phase~~placement ~~1/2~~agents ~~INSPIRE~~for ~~DUCHENNE~~the ~~clinical~~Private ~~trial~~Placement. ACantor ~~copy~~Fitzgerald & ofCo. ~~the~~acted ~~press~~as ~~release~~co-lead ~~issued~~placement inagent ~~connection~~for ~~with~~ the ~~announcement~~Private isPlacement. ~~furnished~~H.C. asWainwright & ~~Exhibit 99~~Co.1 toLLC ~~this~~and ~~Current~~Truist ~~Report~~Securities onInc. ~~Form~~acted 8as co-Kplacement ~~and~~agents isfor ~~incorporated~~the ~~herein~~Private ~~by reference~~Placement.

~~Also~~The onCompany ~~November 3,~~has ~~2025,~~granted the ~~Company~~Investors ~~made~~indemnification ~~available~~rights anwith ~~updated~~respect ~~corporate~~to ~~presentation on~~ its ~~website.~~representations, ~~The~~warranties, ~~corporate~~covenants ~~presentation~~and isagreements ~~furnished~~under asthe ~~Exhibit~~Securities ~~99.2~~Purchase ~~to this Current Report on Form 8-K~~Agreement.

The ~~information~~Private ~~provided~~Placement ~~under~~includes ~~Item~~new ~~7.01~~and ofexisting ~~this~~investors, ~~Current~~including ~~Report~~Perceptive onAdvisors, ~~Form~~Bain ~~8-K~~Capital ~~(including~~Life ~~Exhibits~~Sciences, ~~99.1~~RA ~~and~~Capital ~~99.2)~~Management, ~~shall~~Invus, ~~not~~Vestal bePoint ~~deemed~~Capital, ~~“filed”~~Janus ~~for~~Henderson ~~purposes~~Investors, ofand ~~Section 18~~Deep ofTrack ~~the Exchange Act~~Capital, oramong ~~otherwise~~others. ~~subject~~Each toInvestor ~~the~~has ~~liabilities~~agreed of that ~~section, nor shall~~ it bewill ~~deemed~~not ~~incorporated~~trade ~~by reference~~ in ~~any filing under~~ the ~~Securities~~Company’s ~~Act~~securities oruntil ~~the~~after ~~Exchange Act~~March 11, ~~except as expressly set forth by specific reference in such a filing~~2026.

~~Item~~Pre-Funded ~~8.01.~~Warrants ~~Other Events.~~

OnEach ~~November 3,~~Pre-Funded ~~2025,~~Warrant ~~the~~to ~~Company~~be ~~announced~~issued ~~positive~~in ~~new~~the ~~interim~~Private ~~data~~Placement ~~from~~will ~~its~~have ~~Phase~~an ~~1/2~~exercise ~~INSPIRE~~price ~~DUCHENNE~~of ~~clinical~~$0.001 ~~trial,~~per ~~a Phase 1/2 first-in-human~~share, ~~open-label,~~will ~~single-dose,~~be ~~multicenter~~exercisable ~~trial~~immediately ~~designed to evaluate the safety, tolerability~~ and ~~efficacy~~will ofbe ~~SGT-003~~exercisable inuntil ~~pediatric~~the ~~participants with Duchenne muscular dystrophy at a dose level of 1E14vg/kg. SGT~~Pre-~~003~~Funded Warrant is ~~administered~~exercised asin ~~a one-time intravenous infusion, and a regulatory update~~full.

~~INSPIRE~~Under ~~DUCHENNE~~the terms of the Pre-Funded Warrants, the Company may not effect the exercise of any such warrant, and a holder will not be entitled to exercise any portion of any such warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder’s affiliates, and any other persons whose beneficial ownership of common stock would or could be aggregated with the holder’s for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) would exceed 4.99% or 9.99%, as elected by the holder, of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of such warrant, which percentage may be increased or decreased at the holder’s election upon 61 days’ notice to the Company subject to the terms of such warrants, provided that such percentage may in no event exceed 19.99%.

~~Interim~~Registration ~~Clinical~~Rights ~~Data~~Agreement ~~Update~~

~~The~~Also ~~interim~~on ~~clinical~~March 6, ~~data~~2026, isthe ~~reported~~Company asentered ofinto a ~~September 29,~~registration ~~2025~~rights ~~data~~agreement ~~cutoff~~(the ~~date,~~“Registration Rights Agreement”) with ~~additional~~the ~~safety~~Investors, ~~data~~pursuant ~~reported~~to aswhich the Company agreed to register for resale the Shares and the shares of ~~October 31,~~the ~~2025.~~Company’s Ascommon stock issuable upon exercise of ~~October 31~~the Pre-Funded Warrants (the “Pre-Funded Warrant Shares” and, ~~2025~~together with the Shares, 23the ~~participants~~“Registrable ~~have~~Securities”). ~~been~~Under ~~dosed~~the inRegistration Rights Agreement, the ~~trial.~~Company ~~Enrollment~~has inagreed ~~INSPIRE~~to ~~DUCHENNE~~file isa ~~ongoing~~registration atstatement 15covering ~~clinical~~the ~~trial~~resale ~~sites~~by ~~across~~the Investors of their Registrable Securities no later than 30 days following the ~~United~~closing ~~States,~~of ~~Canada,~~the ~~Italy~~Private ~~and~~Placement (the ~~United~~“Filing ~~Kingdom~~Date”). The Company ~~expects~~has agreed to ~~dose~~use areasonable ~~total~~best ofefforts 30to ~~participants~~cause such registration statement to be declared effective as soon as reasonably practicable and to keep such registration statement effective until the date that all Registrable Securities covered by ~~early~~such ~~2026.~~registration statement have been sold or can be sold without restriction pursuant to Rule 144

~~Statistical~~ and ~~correlations,~~without ~~as measured by~~ the ~~Pearson~~requirement ~~correlation~~to ~~coefficient,~~be ~~were~~in ~~observed~~compliance ~~between~~with ~~Day~~Rule ~~90 SGT-003 microdystrophin therapy and reconstitution of key components of the dystrophin-associated protein complex~~ 144(~~“DAPC”~~c)~~, including beta-sarcoglycan and neuronal nitric oxide synthase~~ (~~“nNOS”~~1). ~~Beta-sarcoglycan~~(or isany asuccessor ~~critical~~thereof) ~~component~~promulgated ofunder the ~~dystrophin~~Securities ~~associated~~Act /of ~~sarcoglycan~~1933, ~~complex~~as ~~that~~amended ~~is highly expressed in cardiac and skeletal muscle and plays a crucial role in maintaining muscle integrity. Myopathy and cardiomyopathy are observed in diseases in which~~ (the ~~sarcoglycan~~“Securities ~~complex is absent~~Act”). ~~nNOS~~The ~~plays~~Company anhas ~~important~~agreed ~~role~~to inbe ~~protecting~~responsible ~~cardiac~~for ~~and~~all ~~skeletal~~fees ~~muscle by improving vasodilation~~ and ~~reducing~~expenses ~~functional~~incurred ~~ischemia~~in ~~and~~connection ~~muscle~~with ~~breakdown. The Company’s microdystrophin construct is~~ the ~~only~~registration ~~microdystrophin~~of ~~gene therapy, approved or investigational, that contains~~ the ~~R16/R17~~Registrable ~~binding domain, which localizes nNOS to the muscle membrane~~Securities.

~~Strong~~In ~~correlations~~the ~~were~~event ~~also~~(i) the ~~observed~~registration ~~between~~statement ~~SGT-003~~has ~~microdystrophin~~not ~~therapy~~been ~~and~~filed ~~improvements~~by inthe ~~several~~Filing ~~biomarkers~~Date, of(ii) the ~~muscle~~registration ~~integrity,~~statement ~~including~~is ~~serum~~not ~~creatine~~declared ~~kinase~~effective prior to the earlier of (~~“CK”~~a), five ~~lactate~~business ~~dehydrogenase~~days after the date on which the Company is notified by the Securities and Exchange Commission (the “~~LDH~~SEC”), ~~aspartate~~that ~~aminotransferase~~the registration statement will not be reviewed by the SEC staff or is not subject to further comment by the SEC staff or (~~“AST”~~b) the ~~and~~75th ~~embryonic~~day ~~myosin~~after ~~heavy~~the ~~chain~~Filing Date, or (~~“eMHC”~~iii) after the registration statement has been declared effective by the SEC, ~~suggesting~~sales cannot be made pursuant to the registration statement for any reason, subject to certain limited exceptions, then the Company has agreed to make pro rata payments to each Investor then holding Registrable Securities as liquidated damages and not as a ~~coordinated~~penalty ~~downstream~~in ~~effect~~an amount equal to one percent (1.0%) of ~~treatment~~the ~~with~~aggregate ~~SGT~~amount invested by such Investor for the Registrable Securities per 30-~~003~~day period or pro rata for any portion thereof for each such month during which such event continues, subject to certain caps set forth in the Registration Rights Agreement.

Correlation of SGT-003 Microdystrophin Levels with Biomarker % Increase from Baseline (N=10)	Pearson Correlation*
Day 90 SGT-003 microdystrophin positive fibers and beta-sarcoglycan positive fibers		0.95
Day 90 SGT-003 microdystrophin positive fibers and nNOS activity		0.95
Correlation of SGT-003 Microdystrophin Levels with Biomarker % Decrease from Baseline (N=7 unless noted)	Pearson Correlation**
Day 90 SGT-003 microdystrophin expression (mass spectrometry) and Day 180 CK		-0.78
Day 90 SGT-003 microdystrophin expression (western blot) and Day 180 CK		-0.71
Day 90 SGT-003 microdystrophin positive fibers (immunofluorescence) and Day 180 CK		-0.54
Day 90 SGT-003 microdystrophin expression (western blot) and Day 180 LDH		-0.71
Day 90 SGT-003 microdystrophin expression (mass spectrometry) and Day 180 LDH		-0.55
Day 90 SGT-003 microdystrophin expression (western blot) and Day 180 AST		-0.54
Day 90 SGT-003 microdystrophin positive fibers and embryonic myosin heavy chain (eMHC) positive fibers (N=10)		-0.51
* A score of 1 indicates a perfect, positive linear relationship; ** A score of -1 indicates a perfect, negative linear relationship; Larger absolute values indicate stronger correlations.

The Company has granted the Investors customary indemnification rights in connection with the registration statement. The Investors have also granted the Company customary indemnification rights in connection with the registration statement.

~~SGT-003,~~The ~~utilizing~~foregoing ~~the~~descriptions ~~Company’s~~of ~~proprietary,~~the ~~rationally~~Securities ~~designed~~Purchase ~~capsid~~Agreement, ~~AAV~~the Pre-~~SLB101,~~Funded ~~has~~Warrants ~~demonstrated~~and ~~strong~~the ~~transduction,~~Registration ~~achieving~~Rights aAgreement ~~mean~~do ofnot 13purport ~~vector~~to ~~copies~~be ~~per~~complete ~~nucleus~~and ~~(N=10)~~are atqualified ~~Day~~in ~~90,~~their ~~along~~entirety ~~with~~by ~~meaningful~~reference ~~restoration~~to ofthe ~~biologic~~full ~~correlates~~text ~~across~~of ~~several~~the ~~measures~~forms of ~~microdystrophin~~Securities Purchase Agreement, ~~components~~Pre-Funded Warrant and Registration Rights Agreement, copies of ~~the~~which ~~DAPC~~are filed as Exhibits 10.1, 4.1 and ~~multiple~~10.2 ~~biomarkers~~to ofthis ~~muscle~~Current ~~integrity~~Report on Form 8-K, respectively, and ~~preservation~~incorporated by reference herein.

InThe representations, warranties and covenants contained in the 10Securities ~~participants~~Purchase ~~(aged~~Agreement ~~5-10)~~and ~~whose~~the ~~Day~~Registration 90Rights ~~biopsies~~Agreement were ~~evaluated~~made assolely offor the ~~September 29,~~benefit ~~2025~~of ~~data~~the ~~cutoff~~parties ~~date,~~thereto and the ~~Company~~placement ~~observed~~agents ~~mean~~expressly ~~microdystrophin~~named ~~expression~~as ofthird-party ~~58%,~~beneficiaries asthereto ~~measured~~and bymay ~~both~~be ~~western~~subject ~~blot~~to ~~and~~limitations ~~mass~~agreed ~~spectrometry~~upon by the contracting parties. Accordingly, ~~and~~the ~~mean~~Securities ~~microdystrophin~~Purchase ~~positive~~Agreement ~~fibers~~and ofthe ~~51%,~~Registration asRights ~~measured~~Agreement are incorporated herein by ~~immunofluorescence.~~reference ~~Furthermore,~~only into ~~each~~provide ofinvestors ~~those~~with 10information ~~participants,~~regarding the ~~Company~~terms ~~observed~~thereof ~~properly~~and ~~localized~~not ~~and~~to ~~restored~~provide ~~beta-sarcoglycan~~investors ~~positive~~with ~~fibers~~any atother ~~the~~factual ~~mean~~information ~~50%~~regarding ~~level~~the asCompany ~~measured~~or byits ~~immunofluorescence~~business, and ~~nNOS~~should ~~activity-positive~~be ~~fibers~~read (ain ~~less~~conjunction ~~sensitive~~with ~~activity~~the ~~assay)~~disclosures atin the ~~mean~~Company’s ~~26%~~periodic ~~level~~reports and other filings with the SEC.

~~Available~~Item ~~Day 360 biopsy data from~~ 2.02 ~~participants~~Results ~~(aged 5) as~~ of ~~September 29,~~Operations ~~2025, demonstrated encouraging~~ and ~~durable~~Financial transduction, achieving a mean of 12 vector copies per nucleus, as well as robust mean microdystrophin expression of 107%, as measured by western blot, and 100%, as measured by mass spectrometry, mean microdystrophin positive fibers of 67% and mean beta-sarcoglycan positive fibers of 70%, both measured by immunofluorescence, and mean nNOS activity-positive fibers of 36%Condition.

~~Additionally,~~Although athe ~~mean~~Company ~~49%~~has ~~reduction~~not infinalized ~~percent~~its ~~eMHC~~full ~~positive~~financial ~~fibers,~~results afor ~~histologic~~the ~~marker~~fourth ofquarter ~~muscle~~and ~~regeneration~~fiscal ~~and~~year ~~disease~~ended ~~progression~~December 31, ~~was observed at Day 90 (N=10). As muscle fibers deteriorate~~2025, ~~muscle~~the ~~stem~~Company ~~cells~~expects ~~are activated~~ to ~~repair~~report ~~and replace damaged muscle fibers; during this process~~cash, ~~new~~cash ~~muscle~~equivalents ~~fibers~~and ~~transiently express eMHC. In Duchenne, this stem cell~~available-~~mediated~~for-sale ~~repair~~securities ~~process is futile because muscle fibers that are developed from stem cells lack dystrophin and therefore will be dystrophic. Consequently, the presence~~ of ~~eMHC~~approximately ~~positive fibers is an informative biomarker of disease progression, signaling constant muscle injury, breakdown and deterioration~~$187.9 million Aas ~~treatment-mediated decrease in eMHC is a favorable observation, and in combination with other markers~~ of ~~reduced muscle injury~~December 31, ~~suggests overall muscle preservation~~2025.

~~Favorable~~The ~~reductions~~estimated ~~across~~cash, acash ~~range~~equivalents and available-for-sale securities figure is preliminary and unaudited, represents management’s estimate as of ~~biomarkers~~the date of ~~muscle~~this ~~injury~~report, ~~and~~is ~~breakdown~~subject ~~were~~to ~~observed~~completion ~~through~~of ~~both~~the ~~Day~~Company’s 90financial closing procedures for the fourth quarter and ~~Day~~fiscal ~~360:~~year ended December 31, 2025, and does not present all necessary information for a complete understanding of the Company’s financial condition as of December 31, 2025, or the Company’s results of operations for the year ended December 31, 2025. The actual financial results may differ materially from the preliminary estimated financial information.

Serum Biomarkers	Day 90 Mean Reductions(N=14 unless noted)			Day 360 Mean Reductions(N=3 unless noted)
Serum creatine kinase (CK)		34	%		42	%
Serum alanine transaminase (ALT)		41	%		29	%
Serum aspartate aminotransferase (AST)		25	%		40	%
Serum lactate dehydrogenase (LDH)*		42	%		46	%
Serum titin**		22	%		25	%
* N=12 participant samples available at Day 90 for LDH (two samples hemolyzed); ** N=11 participant samples available at Day 90 and N=2 samples available at Day 360 for titin, which was batch-analyzed at an earlier cutoff date.

The information provided under Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

~~Interim~~Item ~~Cardiac~~3.02 ~~Monitoring~~Unregistered Sales of Equity Securities.

~~Mean~~The ~~cardiac~~information ~~function~~contained ~~trended~~above ~~into~~in ~~normal~~Item ~~left~~1.01 ~~ventricular~~is ~~ejection~~hereby ~~fraction~~incorporated ~~(“LVEF”)~~by ~~ranges~~reference ~~(60-69%)~~into ~~for~~this ~~all~~Item ~~SGT-003-treated~~3.02. ~~participants~~Based ~~who~~in ~~reached~~part upon the ~~Day~~representations ~~180 follow-up timepoint (N=8) as~~ of the ~~September 29,~~Investors ~~2025,~~in ~~data~~the ~~cutoff~~Securities ~~date.~~Purchase ~~Though~~Agreement, ~~cardiac~~the ~~injury~~offering ~~biomarkers~~ and ~~cardiac~~sale ~~imaging~~of ~~were~~the ~~collected~~Shares ~~primarily~~and ~~for~~the ~~safety~~Pre-Funded ~~analysis,~~Warrants ~~early~~will ~~data~~be ~~may~~exempt ~~indicate~~from aregistration ~~potential~~under ~~for benefit through reduction in troponin I~~ Section 4(~~“cTnI”~~a)(2) ~~and~~of ~~increased~~the ~~systolic~~Securities ~~function as measured by LVEF by echocardiography~~Act. ~~Observed~~The ~~increases in systolic function as measured by LVEF appeared to have been driven largely by participants with low to low-normal systolic function at baseline.~~

~~Mean~~ Shares ~~reductions~~and ~~from~~Pre-Funded ~~baseline~~Warrants have not been registered under the Securities Act or any state securities laws, and the Shares and Pre-Funded Warrants may not be offered or sold in ~~serum~~the ~~cTnI~~United States absent registration with the SEC or an applicable exemption from the registration requirements. The sale of ~~31%~~the atsecurities ~~Day~~will 90not ~~(N=14)~~involve a public offering and ~~70%~~will atbe ~~Day~~made ~~360~~without general solicitation or general advertising. The Investors represented that they are institutional “accredited investors” as defined in Rule 501(N=a)(1), (2), (3) ~~were~~or ~~observed~~(7) under ~~with~~the ~~reductions~~Securities ~~driven~~Act byor ~~participants~~“qualified ~~who~~institutional ~~entered~~buyers” within the ~~trial~~meaning ~~with~~of ~~elevated~~Rule ~~baseline~~144A ~~cTnI~~under ~~levels.~~the ~~cTnI~~Securities isAct, anand ~~important~~that ~~marker~~they ~~that~~are ~~can~~acquiring bethe ~~predictive~~Shares and Pre-Funded Warrants for investment purposes only and not with a view to any resale, distribution or other disposition of ~~severe~~the ~~cardiac~~Shares ~~disease~~and Pre-Funded Warrants in ~~neuromuscular~~violation ~~diagnoses~~of the United States federal securities laws.

~~Interim~~Item ~~Safety~~8.01 ~~Update~~Other Events.

~~SGT-003~~Based ~~has~~upon ~~been~~the ~~generally~~Company’s ~~well~~current ~~tolerated~~operating inplan, the 23Company ~~participants~~estimates ~~dosed~~that asthe ofnet ~~October 31~~proceeds from the Private Placement, ~~2025.~~together ~~Steroids~~with ~~alone~~the ~~were~~Company’s ~~utilized~~existing ascash, cash equivalents and available-for-sale securities, will enable the ~~prophylactic~~Company ~~immunomodulation~~to ~~regimen.~~fund ~~Signals~~its operating expenses and capital expenditure requirements into the first half of ~~asymptomatic~~2028. The Company expects to use the net proceeds from the Private Placement, together with its existing cash, cash equivalents and ~~self~~available-~~resolving~~for-sale ~~platelet~~securities, ~~declines~~to fund ongoing pipeline development programs, business development activities, and ~~thrombocytopenia~~the ~~observed~~remainder infor ~~early~~general ~~participants~~and inadministrative expenses and other general corporate purposes. The Company has based this estimate on assumptions that may prove to be wrong, and the ~~trial~~Company ~~have~~could ~~been~~use ~~ameliorated~~its available capital resources sooner than it currently expects, in ~~subsequent~~which ~~participants~~case it would need to obtain additional funding, which may not be available to the Company on acceptable terms, or at all. The Company does not expect that its existing cash, cash equivalents and available-for-sale securities and net proceeds from this Private Placement alone will be sufficient to enable the Company to fund the completion of the development of any of its product candidates.

As of October 31, 2025, there was one treatment-related serious adverse event (“SAE”) reported in the INSPIRE DUCHENNE trial. This SAE was identified as a Grade 3 immune-mediated myositis which, importantly, was not associated with muscle pain or weakness, and occurred in a participant who had a large deletion in a region coded for by SGT-003’s microdystrophin. The participant promptly responded to steroid treatment with all clinical symptoms noted at presentation resolving and with muscle biomarkers, including CK, declining well below baseline levels. This SAE was reviewed by the trial data and safety monitoring board with the recommendation to continue dosing without interruption.

As of October 31, 2025, the most common treatment related adverse events (n=23) included nausea (73.9%), vomiting (69.6%), decreased appetite (47.8%), thrombocytopenia /platelet count decreased (47.8%), and headache (26.1%).

In Duchenne, transaminase elevations are the result of ongoing muscle injury as opposed to liver injury. Therapeutic interventions that lead to reductions in transaminases therefore indicate muscle protection in the setting of an avoidance of demonstrable liver injury, especially when more specific liver injury markers remain stable. As of the September 29, 2025, data cutoff date, the Company observed a mean alanine transaminase (“ALT”) reduction of 41% (N=14), a mean AST reduction of 25% (N=14) and stable mean gamma-glutamyl transferase levels through Day 90 (N=14). Mean reductions of 40% AST and 29% ALT were observed in the three participants who reached the Day 360 follow-up. There have been no cases of drug-induced liver injury (DILI) observed as of October 31, 2025 (N=23).

SGT-003 Regulatory Update

The Company plans to meet with the U.S. Food and Drug Administration (the “FDA”) in the first half of 2026 to discuss potential registrational pathways, including accelerated approval pathways, for SGT-003. The Company continues to dose participants in the INSPIRE DUCHENNE trial in the interim, with additional participant safety, clinical activity and functional data expected to enable a more robust discussion with the FDA.

Critically, the Company believes it has aligned with the FDA on SGT-003’s potency assay strategy and will continue additional commercial-readiness CMC activities, with its process performance qualification manufacturing batches expected to be completed in 2026.

IMPACT DUCHENNE

In October 2025, the Company activated the first clinical trial site and began participant screening for IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled clinical trial assessing SGT-003. IMPACT DUCHENNE will be conducted in pediatric participants outside of the United States and was designed to support potential ex-U.S. regulatory authorizations. The Company has received regulatory approvals to conduct IMPACT DUCHENNE in both Canada and Australia, and the Company plans to expand the trial into additional countries, subject to receipt of regulatory approvals.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of ~~The~~the Private Securities Litigation Reform Act of 1995, including statements regarding ~~future~~the ~~expectations,~~anticipated ~~plans~~closing ~~and~~of ~~prospects for~~ the ~~Company~~Private Placement; the ~~ability~~anticipated toproceeds ~~successfully~~from ~~achieve~~the ~~and~~Private ~~execute~~Placement; on the ~~company’s~~filing ~~goals,~~of ~~priorities~~a ~~and~~registration ~~key~~statement ~~clinical~~to ~~and~~register ~~preclinical~~the ~~milestones;~~resale ~~strategies~~of ~~and expectations for~~ the ~~Company’s~~Shares ~~SGT-003, SGT-212, SGT-501~~ and ~~SGT~~Pre-~~601~~Funded ~~programs;~~Warrant ~~expectations~~Shares ~~for~~to ~~site~~be ~~activations,~~issued ~~planned~~and ~~enrollment,~~sold ~~planned~~in ~~regulatory~~the ~~interactions~~Private ~~and~~Placement; the ~~potential~~Company’s ~~approval~~preliminary ~~pathways~~and ~~for~~unaudited ~~SGT-003;~~estimated ~~plans~~cash, ~~for~~cash ~~enrollment~~equivalents inand ~~the~~available-for-sale ~~clinical~~securities ~~trial~~as of ~~SGT-212~~December 31, 2025; ~~timing~~the ofCompany’s ~~planned~~anticipated ~~clinical~~cash ~~trial of SGT-501~~runway; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to,: ~~risks~~market ~~associated with the Company’s ability to advance SGT-003, SGT-212, SGT-501, SGT-601~~ and other ~~preclinical~~financial ~~programs~~conditions and ~~capsid~~the ~~libraries~~impact onof ~~the~~general ~~timelines~~economic, ~~expected~~industry or atpolitical ~~all;~~conditions ~~obtain~~in ~~and maintain necessary approvals and designations from~~ the ~~FDA~~United ~~and~~States ~~other~~or ~~regulatory authorities~~internationally; ~~replicate~~whether inthe ~~clinical~~conditions ~~trials~~for ~~positive~~the ~~results~~closing ~~found in preclinical studies and early-stage clinical trials~~ of the ~~Company’s~~Private ~~product~~Placement ~~candidates;~~will ~~obtain,~~be ~~maintain or protect intellectual property rights related to its product candidates~~satisfied; ~~compete~~and ~~successfully~~uncertainties ~~with~~as ~~other companies that are seeking~~ to ~~develop~~the ~~Duchenne, Friedreich~~Company’s ~~ataxia~~preliminary and ~~other~~unaudited ~~neuromuscular~~estimated ~~and~~cash, ~~cardiac~~cash ~~treatments~~equivalents and ~~gene~~available-for-sale ~~therapies;~~securities ~~manage~~as ~~expenses;~~of ~~raise the substantial additional capital needed~~December 31, ~~on the timeline necessary~~2025, towhich ~~continue~~are ~~development~~estimates ofbased ~~SGT-003,~~on ~~SGT-212,~~preliminary ~~SGT-501, SGT-601~~ and ~~other~~unaudited ~~candidates;~~information, ~~and~~subject ~~achieve~~to ~~its~~the ~~other~~completion ~~business~~of ~~objectives~~the ~~and~~Company’s ~~continue~~financial asclosing ~~a going concern~~procedures. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the ~~Securities and Exchange Commission, and other filings that the Company may make with the Securities and Exchange Commission in the future~~SEC. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

ExhibitNo.		Description
Exhibit No.		Description
99.1		Press Release dated November 3, 2025
4.1		Form of Pre-Funded Warrant.
99.2		Solid Biosciences Inc. Presentation November 2025
10.1		Form of Securities Purchase Agreement, dated March 6, 2026, by and among the Company and the other parties thereto.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)
10.2		Form of Registration Rights Agreement, dated March 6, 2026, by and among the Company and the other parties thereto.
104		Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~as amended,~~ the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SOLID BIOSCIENCES INC.
Date: November 3, 2025	By:	/s/ Alexander Cumbo
Date: March 6, 2026	By:	/s/ Alexander Cumbo
	Name:	Alexander Cumbo
	Title:	Chief Executive Officer

Filing Compare · Solid Biosciences Inc.